We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Randox Look Forward to AACC/ASCLS Clinical Lab Expo 2011

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Randox (booth #1301) is proud to be an exhibitor at the upcoming AACC/ASCLS Annual Meeting and Clinical Lab Expo to be held in Atlanta 26th - 28th July 2011.

The AACC/ASCLS is the largest clinical lab expo in the world. This year it is set to be as popular as ever. Hosting more than 650 exhibitors covering 1,800 booths the 2011 AACC Clinical Lab Expo will cover the entire clinical diagnostic spectrum from automation to OEM.

At Randox, we are excited to showcase all our latest innovations. Visitors to our booth #1301 will witness new and improved technologies that will make a real difference to laboratory work.

Our product portfolio is vast, ranging from chemistry analysers and QC to molecular diagnostics and biochip multiplex arrays. As a result we are capable of meeting the needs of many different laboratory types. Stop by our booth to see how we can fulfil your laboratory needs.

We are passionate about high quality, reliable diagnostic solutions. Our featured products at this year’s AACC/ASCLS strongly reflect this. This will include the latest addition to the RX series of clinical chemistry analysers, the RX suzuka - a fully automated, discrete random access clinical analyser capable of running up to 1200 tests per hour including ISEs. The new addition to the Biochip analysers will also be on show.

The Evidence Evolution is the world’s first fully automated random access biochip testing platform. Utilizing the unique multiplexing Biochip Array Technology, it offers advanced consolidation and patient profiling.

Our Cardiology Division offer the latest biomarkers for detection of Cardiovascular Disease (CVD) consisting of a complete lipid profile including Lp(a), an automated assay for the highly sensitive and specific biomarker H-FABP and the innovative TxB Cardio assay which provides a urinary assessment of Aspirin resistance or non-responsiveness allowing clinicians to more effectively tailor aspirin therapy.